Shanghai - Delayed Quote CNY

Henan Lingrui Pharmaceutical Co., Ltd. (600285.SS)

22.00 +2.00 (+10.00%)

At close: October 30 at 3:00:01 PM GMT+8

Chart Range Bar

Loading chart for 600285.SS

Previous Close 20.00
Open 21.66
Bid 22.00 x --
Ask --
Day's Range 21.28 - 22.00
52 Week Range 18.51 - 23.65
Volume 20,219,643
Avg. Volume 9,699,960
Market Cap (intraday) 12.477B
Beta (5Y Monthly) --
PE Ratio (TTM) 15.07
EPS (TTM) 1.46
Earnings Date --
Forward Dividend & Yield 1.10 (5.00%)
Ex-Dividend Date Jun 11, 2026
1y Target Est 26.20

Henan Lingrui Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of drugs in China. It operates through Medical and Healthcare Division; and Others segments. The company offers its products in ten dosage forms, such as adhesive plasters, tablets, capsules, granules, and tinctures, etc. for various indications, including orthopedic, cardiovascular, cerebrovascular, dermatology, pediatrics, respiratory, nutritional supplements, and anesthesiology. Its products include Tongluoqutong plasters, Peiyuantongnao capsules, Danlutongdu tablets, stomachache free tablets, and Shenqi Hypoglycemic capsules. The company also engages in industrial and real estate investment; technology research and development; ecological agriculture; and high-tech activities. Henan Lingrui Pharmaceutical Co., Ltd. was founded in 1992 and is headquartered in Xinyang, China.

www.lingrui.com

2,789

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Drug Manufacturers - Specialty & Generic

Industry

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is SSE Composite Index (000001.SS) .

YTD Return

600285.SS

11.82%

SSE Composite Index (000001.SS)

9.32%

1-Year Return

600285.SS

3.75%

SSE Composite Index (000001.SS)

9.73%

3-Year Return

600285.SS

58.59%

SSE Composite Index (000001.SS)

19.11%

5-Year Return

600285.SS

150.43%

SSE Composite Index (000001.SS)

1.46%

Earnings Per Share

No Earnings Per Share available for this ticker

Revenue vs. Earnings

yearly Annual

quarterly Quarterly

yearly Annual

quarterly Quarterly

Q4 FY15

Revenue --

Earnings 25.3M

Profit Margin 0.00%

FY15

10M

15M

20M

25M

0.0%

Analyst Price Targets

26.20

26.20 Average

22.00 Current

26.20 High

Analyst Recommendations

Strong Buy
Buy
Hold
Underperform
Sell

Valuation Measures

  
  
 Annual 

Market Cap
Enterprise Value
Trailing P/E
Forward P/E
PEG Ratio (current)
Price/Sales (ttm)
Price/Book (mrq)
Enterprise Value/Revenue
Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

Profit Margin

20.94%
Return on Assets (ttm)

9.49%
Return on Equity (ttm)

24.55%
Revenue (ttm)

3.95B
Net Income Avi to Common (ttm)

827.37M
Diluted EPS (ttm)

1.46

Balance Sheet and Cash Flow

Total Cash (mrq)

1.02B
Total Debt/Equity (mrq)

9.22%
Levered Free Cash Flow (ttm)

98.67M

600329.SS Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited

40.30 +0.80%

600380.SS Joincare Pharmaceutical Group Industry Co.,Ltd.

10.05 +1.01%

600332.SS Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited

19.61 +1.29%

600267.SS Zhejiang Hisun Pharmaceutical Co., Ltd.

12.95 +1.81%

600252.SS Guangxi Wuzhou Zhongheng Group Co., Ltd

2.1400 -2.73%

U.S. markets closed

Henan Lingrui Pharmaceutical Co., Ltd. (600285.SS)

8.27%

15.91%

-1.61%

6.23%

-1.43%

105.03%

251.64%

Henan Lingrui Pharmaceutical Co., Ltd. Overview Drug Manufacturers - Specialty & Generic / Healthcare

Full Time Employees

Fiscal Year Ends

Sector

Industry

Recent News

Performance Overview

YTD Return

1-Year Return

3-Year Return

5-Year Return

Earnings Trends

Earnings Per Share

Revenue vs. Earnings

Analyst Insights

Analyst Price Targets

Analyst Recommendations

Statistics

Valuation Measures

Financial Highlights

Profitability and Income Statement

Balance Sheet and Cash Flow

Company Insights

Research Reports

People Also Watch